Aligos Therapeutics is a leading brand in the biopharmaceutical and biotechnology industries, offering innovative solutions to address various medical challenges. With a qualified Management Team and Board of Directors, they strive for excellence in their products and services. Their product pipeline includes cutting-edge therapies designed to combat infectious diseases and respiratory infections.

They prioritize research and development in small molecules and oligonucleotides, leveraging over 30 years of experience in medicinal chemistry and drug discovery. Under the leadership of the Chairman and CEO, Lawrence M. Blatt, Ph.

D., M. B. A., who has an extensive background in the industry, the company has achieved remarkable milestones.

They have formed strategic partnerships and published scientific presentations, showcasing their commitment to scientific excellence. Aligos Therapeutics attracts top talent with experts such as President Leonid Beigelman, Ph. D., and Executive Vice President, Chief Scientific Officer Julian Symons, D.

Phil. Their deep expertise and knowledge enhance the brand's ability to deliver breakthrough therapies. With a dedicated focus on research, impactful partnerships, and a highly qualified team, Aligos Therapeutics is poised to revolutionize healthcare with their state-of-the-art treatments.

Join them on their mission to make a significant impact on patients' lives